Interleukin-1 receptor antagonist exerts agonist activity in the hippocampus independent of the interleukin-1 type I receptor

Journal of Neuroimmunology

Volumn 137, Issue 1-2, 2003, Pages 117-124

  Loscher, Christine E ^a   Mills, Kingston H G ^a   Lynch, Marina A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Glutamate; IL 1 type I receptor; Interleukin 1ra; Interleukin 1 ; JNK; LTP

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; RECEPTOR SUBTYPE;

AGONIST; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; HIPPOCAMPUS; LONG TERM POTENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPTOSOME;

EID: 0037376813     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(03)00072-9     Document Type: Article

References (30)

1. Arend W.P., Malyak M., Guthridge C.J., Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16:1998;27-55.
2. Bianchi M., Clavenna A., Bondiolotti G.P., Ferrario P., Panerai A.E. GM-CSF affects hypothalamic neurotransmitter levels in mice: involvement of interleukin-1. NeuroReport. 8:1997;3587-3590.
3. Born T.L., Smith D.E., Garka K.E., Renshaw B.R., Bertles J.S., Sims J.E. Identification and characterization of two members of a novel class of the interleukin receptor (IL-1R) family. J. Biol. Chem. 275:2000;29946-29954.
4. Carrie A., Jun L., Bienvenu T., Vinet M.C., McDonell N., Couvert P., Zemni R., Cardona A., Van Buggenhout G., Frints S., Hamel B., Moraine C., Ropers H.H., Strom T., Howell G.R., Whittaker A., Ross M.T., Kahn A., Fryns J.P., Beldjord C., Marynen P., Chelly J. A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nat. Genet. 23:1999;25-31.
5. 3H]serotonin and histamine release by rat basophilic leukemia-2H3 cells. Ann. N. Y. Acad. Sci. 832:1997;223-232.
6. Coogan A.N., O'Neill L.A., O'Connor J.J. The P38 mitogen-activated protein kinase inhibitor SB203580 antagonizes the inhibitory effects of interleukin-1beta on long-term potentiation in the rat dentate gyrus in vitro. Neuroscience. 93:1999;57-69.
7. Greenfeder S.A., Varnell T., Powers G., Lombard-Gillooly K., Shuster D., McIntyre K.W., Ryan D.E., Levin W., Madison V., Ju G. Insertion of a structural domain of interleukin (IL)-1 beta confers agonist activity to the IL-1 receptor antagonist. Implications for IL-1 bioactivity. J. Biol. Chem. 270:1995;22460-22466.
8. Hirsch E., Irikura V.M., Paul S.M., Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11008-11013.
9. Huang S., Konieczkowski M., Schelling J.R., Sedor J.R. Interleukin-1 stimulates Jun N-terminal/stress-activated protein kinase by an arachidonate-dependent mechanism in mesangial cells. Kidney Int. 55:1999;1740-1749.
10. Kumar S., McDonnell P.C., Lehr R., Tierney L., Tzimas M.N., Griswold D.E., Capper E.A., Tal-Singer R., Wells G.I., Doyle M.L., Young P.R. Identification and initial characterization of four novel members of the interleukin-1 family. J. Biol. Chem. 275:2000;10308-10314.
11. Loddick S.A., Wong M.L., Bongiorno P.B., Gold P.W., Licinio J., Rothwell N.J. Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochem. Biophys. Res. Commun. 234:1997;211-215.
12. Loscher C.E., Donnelly S., Mills K.H., Lynch M.A. Interleukin-1beta-dependent changes in the hippocampus following parenteral immunization with a whole cell pertussis vaccine. J. Neuroimmunol. 111:2000;68-76.
13. Lynch M.A. Age-related impairment in long-term potentiation in hippocampus: a role for the cytokine, interleukin-1 beta? Prog. Neurobiol. 56:1998;571-589.
14. Lynch A.M., Lynch M.A. The age-related increase in IL-1 type I receptor in rat hippocampus is coupled with an increase in caspase-3 activation. Eur. J. Neurosci. 15:2002;1779-1788.
15. Maroney A.C., Glicksman M.A., Basma A.N., Walton K.M., Knight E. Jr., Murphy C.A., Bartlett B.A., Finn J.P., Angeles T., Matsuda Y., Neff N.T., Dionne C.A. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J. Neurosci. 18:1998;104-111.
16. McGahon B., Lynch M.A. The synergism between metabotropic glutamate receptor activation and arachidonic acid on glutamate release is occluded by induction of long-term potentiation in the dentate gyrus. Neuroscience. 72:1996;847-855.
17. Murray C.A., Lynch M.A. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J. Neurosci. 18:1998;2974-2981.
18. Murray C.A., McGahon B., McBennett S., Lynch M.A. Interleukin-1 beta inhibits glutamate release in hippocampus of young, but not aged, rats. Neurobiol. Aging. 18:1997;343-348.
19. O'Donnell E., Vereker E., Lynch M.A. Age-related impairment in LTP is accompanied by enhanced activity of stress-activated protein kinases: analysis of underlying mechanisms. Eur. J. Neurosci. 12:2000;345-352.
20. O'Neill L.A., Dinarello C.A. The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol. Today. 21:2000;206-209.
21. Park D.S., Stefanis L., Yan C.Y., Farinelli S.E., Greene L.A. Ordering the cell death pathway. Differential effects of BCL2, an interleukin-1-converting enzyme family protease inhibitor, and other survival agents on JNK activation in serum/nerve growth factor-deprived PC12 cells. J. Biol. Chem. 271:1996;21898-21905.
22. Rada P., Mark G.P., Vitek M.P., Mangano R.M., Blume A.J., Beer B., Hoebel B.G. Interleukin-1 beta decreases acetylcholine measured by microdialysis in the hippocampus of freely moving rats. Brain Res. 550:1991;287-290.
23. Rizzo M.T., Carlo-Stella C. Arachidonic acid mediates interleukin-1 and tumor necrosis factor-alpha-induced activation of the c-jun amino-terminal kinases in stromal cells. Blood. 88:1996;3792-3800.
24. Rothwell N., Allan S., Toulmond S. The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. J. Clin. Invest. 100:1997;2648-2652.
25. Schneider H., Pitossi F., Balschun D., Wagner A., del Rey A., Besedovsky H.O. A neuromodulatory role of interleukin-1beta in the hippocampus. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7778-7783.
26. Sims J.E. IL-1 and IL-18 receptors, and their extended family. Curr. Opin. Immunol. 14:2002;117-122.
27. Sims J.E., Gayle M.A., Slack J.L., Alderson M.R., Bird T.A., Giri J.G., Colotta F., Re F., Mantovani A., Shanebeck K.et al. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc. Natl. Acad. Sci. U. S. A. 90:1993;6155-6159.
28. Touzani O., Boutin H., LeFeuvre R., Parker L., Miller A., Luheshi G., Rothwell N. Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. J. Neurosci. 22:2002;38-43.
29. Vereker E., Campbell V., Roche E., McEntee E., Lynch M.A. Lipopolysaccharide inhibits long term potentiation in the rat dentate gyrus by activating caspase-1. J. Biol. Chem. 275:2000;26252-26258.
30. Vereker E., O'Donnell E., Lynch M.A. The inhibitory effect of interleukin-1beta on long-term potentiation is coupled with increased activity of stress-activated protein kinases. J. Neurosci. 20:2000;6811-6819.